US-based Regeneron Pharmaceuticals (NASDAQ: REGN) has reported its financial details for the third quarter of 2024, with revenues reaching USD 3.72 billion, marking an 11% increase year-on-year (YOY). Product sales grew by 9% YOY to USD 1.946 billion, while collaboration revenues stood at USD 1.774 billion, up 12.5% YOY.
In terms of drug performance, Eylea HD and Eylea sales increased by 3% YOY to USD 1.54 billion. Global sales of Libtayo (cemiplimab) reached USD 289 million, up 25% YOY. Praluent (alirocumab) generated USD 53 million in the US, up 33% YOY. Evkeeza achieved USD 32 million in the US, up 68%. Additionally, Inmazeb, an Ebola infection drug, recorded global sales of USD 35 million during the period.
Regarding cooperation revenues, those derived from Sanofi were USD 1.263 billion, up 19%, primarily driven by Dupixent (dupilumab); revenues from Bayer rose 4% YOY to USD 391 million.- Flcube.com
